Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The day is coming when Humira (adalimumab) will no longer dominate the biggest-selling drug charts, but not next year. AbbVie’s powerhouse again tops sales forecasts, with nearly US$20 billion in expected sales in 2021 (Table 1). To put Humira’s recent dominance of the industry into context, from its launch in 2003 until the end of June 2020, the anti-TNF monoclonal antibody (mAb) generated $165.8 billion in cumulative sales. So, this year, it has snatched the crown for the industry’s most successful drug from Lipitor (atorvastatin), a cholesterol-lowering drug that racked up ~$160 billion in full-year sales in 23 years on the market.